Radar›Companies›Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 2
United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 2

A five-company surgical and medical instruments and apparatus cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderDexcom · 55
Strongest available pathMerit · +24.8%
Widest latest marginGlobus Medical · 18.3%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DXCM · Nasdaq

Dexcom

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1999WILMINGTON$34.27B market cap
View full Companies Radar profile
55Moderate
Snapshot price$90.82as of page date
Monthly-close return-32.5%five-year window
FY2025 revenue$4.66BDEXCOM INC
Net margin17.9%FY2025
P/E snapshot35.9xone ratio, not a verdict
Prism attention14.1%share across these five
Filing track recordRevenue, USD billions
+90.4%
$0$1.6B$3.1B$4.7BFY2021: $2.449BFY2022: $2.910BFY2023: $3.622BFY2024: $4.033BFY2025: $4.662B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 17.5%
52-week position95% through range
$54.11$92.59
News mentions8.5K
Community mentions83.7Kpartial coverage
U.S.-scope patents4656
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal82/100
Management stability90/100
Market position7/100
Capital-event signal64/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 11 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2GMED · NYSE

Globus Medical

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2003WILMINGTON$11.14B market cap
View full Companies Radar profile
50Moderate
Snapshot price$82.97as of page date
Monthly-close return+1.2%five-year window
FY2025 revenue$2.94BGLOBUS MEDICAL INC
Net margin18.3%FY2025
P/E snapshot21.2xone ratio, not a verdict
Prism attention4.4%share across these five
Filing track recordRevenue, USD billions
+206.7%
$0$1.0B$2.0B$2.9BFY2021: $0.958BFY2022: $1.023BFY2023: $1.568BFY2024: $2.519BFY2025: $2.939B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 32.3%
52-week position61% through range
$54.15$101.4
News mentions2.6K
Community mentions61partial coverage
U.S.-scope patents5179
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal77/100
Management stability90/100
Market position23/100
Capital-event signal20/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 21 M&A involvements, 5 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3MMSI · Nasdaq

Merit

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2007Santa Rosa, California$5.40B market cap
View full Companies Radar profile
48Cautious
Snapshot price$90.49as of page date
Monthly-close return+24.8%five-year window
FY2025 revenue$1.52BMERIT MEDICAL SYSTEMS INC
Net margin8.5%FY2025
P/E snapshot37.2xone ratio, not a verdict
Prism attention72.4%share across these five
Filing track recordRevenue, USD billions
+41.0%
$0$0.5B$1.0B$1.5BFY2021: $1.075BFY2022: $1.151BFY2023: $1.257BFY2024: $1.357BFY2025: $1.516B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 9.0%
52-week position88% through range
$59.74$94.75
News mentions43.7K
Community mentions0partial coverage
U.S.-scope patents5017
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal75/100
Management stability90/100
Market position25/100
Capital-event signal25/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 18 M&A involvements, 12 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4WST · NYSE

West Pharmaceutical Services

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1923EXTON$23.75B market cap
View full Companies Radar profile
45Cautious
Snapshot price$337.5as of page date
Monthly-close return-23.4%five-year window
FY2025 revenue$3.07BWEST PHARMACEUTICAL SERVICES INC
Net margin16.1%FY2025
P/E snapshot43.3xone ratio, not a verdict
Prism attention4.0%share across these five
Filing track recordRevenue, USD billions
+8.6%
$0$1.0B$2.0B$3.1BFY2021: $2.832BFY2022: $2.887BFY2023: $2.950BFY2024: $2.893BFY2025: $3.074B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.1%
52-week position70% through range
$223.8$386.0
News mentions2.4K
Community mentions12partial coverage
U.S.-scope patents459
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal82/100
Management stability90/100
Market position8/100
Capital-event signal15/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 1 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5IART · Nasdaq

Integra LifeSciences

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1989Plainsboro, New Jersey$1.31B market cap
View full Companies Radar profile
42Cautious
Snapshot price$16.89as of page date
Monthly-close return-77.6%five-year window
FY2025 revenue$1.64BINTEGRA LIFESCIENCES HOLDINGS CORP
Net margin-31.6%FY2025
P/E snapshot6.5xone ratio, not a verdict
Prism attention5.1%share across these five
Filing track recordRevenue, USD billions
+6.0%
$0$0.5B$1.1B$1.6BFY2021: $1.542BFY2022: $1.558BFY2023: $1.542BFY2024: $1.611BFY2025: $1.635B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.5%
52-week position69% through range
$8.70$20.49
News mentions3.1K
Community mentions13partial coverage
U.S.-scope patents279
Prism Insights

What sits behind the readiness signal

Observed risk 8/100higher means more observed risk
Earnings signal55/100
Management stability90/100
Market position24/100
Capital-event signal39/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 43 M&A involvements, 3 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 0 regulatory and 1 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Merit
+24.8%
Globus Medical
+1.2%
West Pharmaceutical Services
-23.4%
Dexcom
-32.5%
Integra LifeSciences
-77.6%

Latest revenue

USD billions, official filing scope shown on each company card.

Dexcom
$4.66B
West Pharmaceutical Services
$3.07B
Globus Medical
$2.94B
Integra LifeSciences
$1.64B
Merit
$1.52B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Globus Medical
18.3%
Dexcom
17.9%
West Pharmaceutical Services
16.1%
Merit
8.5%
Integra LifeSciences
-31.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Merit
72.4%
Dexcom
14.1%
Integra LifeSciences
5.1%
Globus Medical
4.4%
West Pharmaceutical Services
4.0%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Merit leads the conversation

It holds 72.4% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $1.52B.

Price path

Merit leads the available price paths

Its monthly-close return is +24.8% for the five-year window. At the other end, Integra LifeSciences is -77.6% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Globus Medical has the widest latest margin

Its FY2025 net margin is 18.3%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Integra LifeSciences shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 6.5x while its five-year window price return is -77.6%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DXCM

Dexcom

8,512available Prism news records

Prism top themes

Price action & investor response
415
Macro demand & rates
256
Earnings & financial performance
206
Legal, arbitration & regulatory
148
Capital allocation & transactions
71

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-18.8%1,611 latest 12m vs 1,983 prior 12m
2024-01: 123 mentions2024-02: 102 mentions2024-03: 120 mentions2024-04: 67 mentions2024-05: 86 mentions2024-06: 145 mentions2024-07: 179 mentions2024-08: 236 mentions2024-09: 206 mentions2024-10: 203 mentions2024-11: 153 mentions2024-12: 168 mentions2025-01: 184 mentions2025-02: 238 mentions2025-03: 103 mentions2025-04: 102 mentions2025-05: 111 mentions2025-06: 100 mentions2025-07: 106 mentions2025-08: 101 mentions2025-09: 191 mentions2025-10: 122 mentions2025-11: 140 mentions2025-12: 121 mentions2026-01: 141 mentions2026-02: 178 mentions2026-03: 121 mentions2026-04: 184 mentions2026-05: 167 mentions2026-06: 39 mentions2024-012026-06

Machine-classified coverage tone

80.6% positive+18.0 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

continuous glucose monitor 247remote glucose monitoring 232flash glucose monitoring 198smartwatch health monitor 188interstitial glucose monitoring 166advanced diabetes devices 145self-monitoring blood glucose 140glucose trends analysis 131

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-28 · trend and themes shown through 2026-06
Areas of research · GMED

Globus Medical

2,631available Prism news records

Prism top themes

Earnings & financial performance
117
Price action & investor response
86
Leadership & governance
45
Legal, arbitration & regulatory
28
Macro demand & rates
21

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-14.1%401 latest 12m vs 467 prior 12m
2024-01: 31 mentions2024-02: 31 mentions2024-03: 17 mentions2024-04: 20 mentions2024-05: 25 mentions2024-06: 35 mentions2024-07: 30 mentions2024-08: 59 mentions2024-09: 20 mentions2024-10: 26 mentions2024-11: 28 mentions2024-12: 9 mentions2025-01: 23 mentions2025-02: 96 mentions2025-03: 59 mentions2025-04: 23 mentions2025-05: 79 mentions2025-06: 15 mentions2025-07: 23 mentions2025-08: 31 mentions2025-09: 23 mentions2025-10: 28 mentions2025-11: 40 mentions2025-12: 25 mentions2026-01: 28 mentions2026-02: 47 mentions2026-03: 42 mentions2026-04: 59 mentions2026-05: 41 mentions2026-06: 14 mentions2024-012026-06

Machine-classified coverage tone

91.8% positive+7.4 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

earnings report 35quarterly results 28annual earnings 26financial report 24profit statement 22quarterly financials 21neurosurgery robotics 20robotic surgery 20

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-16–2026-06-19 · trend and themes shown through 2026-06
Areas of research · MMSI

Merit

43,699available Prism news records

Prism top themes

Leadership & governance
165
Legal, arbitration & regulatory
120

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-25.3%4,534 latest 12m vs 6,066 prior 12m
2024-03: 348 mentions2024-04: 283 mentions2024-05: 450 mentions2024-06: 320 mentions2024-07: 503 mentions2024-08: 326 mentions2024-09: 425 mentions2024-10: 424 mentions2024-11: 424 mentions2024-12: 376 mentions2025-01: 527 mentions2025-02: 870 mentions2025-03: 553 mentions2025-04: 566 mentions2025-05: 450 mentions2025-06: 429 mentions2025-07: 453 mentions2025-08: 569 mentions2025-09: 393 mentions2025-10: 433 mentions2025-11: 478 mentions2025-12: 431 mentions2026-01: 369 mentions2026-02: 511 mentions2026-03: 526 mentions2026-04: 684 mentions2026-05: 623 mentions2026-06: 76 mentions2026-07: 9 mentions2026-08: 1 mentions2024-032026-08

Machine-classified coverage tone

80.4% positive+4.9 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

college entrance exams 455admissions testing 421master's admission 305graduate admission criteria 274global tournaments 167exam prep courses 112academic tenure 108faculty advancement 108

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-08-01 · trend and themes shown through 2026-08
Areas of research · WST

West Pharmaceutical Services

2,382available Prism news records

Prism top themes

Price action & investor response
201
Earnings & financial performance
119
Legal, arbitration & regulatory
77
Macro demand & rates
75
Capital allocation & transactions
70

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+110.1%603 latest 12m vs 287 prior 12m
2024-01: 20 mentions2024-02: 35 mentions2024-03: 20 mentions2024-04: 26 mentions2024-05: 20 mentions2024-06: 9 mentions2024-07: 14 mentions2024-08: 16 mentions2024-09: 21 mentions2024-10: 21 mentions2024-11: 18 mentions2024-12: 13 mentions2025-01: 20 mentions2025-02: 54 mentions2025-03: 27 mentions2025-04: 27 mentions2025-05: 32 mentions2025-06: 24 mentions2025-07: 32 mentions2025-08: 24 mentions2025-09: 30 mentions2025-10: 58 mentions2025-11: 28 mentions2025-12: 31 mentions2026-01: 72 mentions2026-02: 107 mentions2026-03: 60 mentions2026-04: 70 mentions2026-05: 71 mentions2026-06: 20 mentions2024-012026-06

Machine-classified coverage tone

91.6% positive+6.5 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

smart packaging 69anti-counterfeiting packaging 56temperature-sensitive packaging 48stock price 39drug distribution 33stock performance 32investment deal 21earnings report 20

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-06-19 · trend and themes shown through 2026-06
Areas of research · IART

Integra LifeSciences

3,074available Prism news records

Prism top themes

Price action & investor response
72
Earnings & financial performance
44
Leadership & governance
43
Capital allocation & transactions
22
Legal, arbitration & regulatory
7

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+12.2%396 latest 12m vs 353 prior 12m
2024-01: 31 mentions2024-02: 33 mentions2024-03: 30 mentions2024-04: 21 mentions2024-05: 37 mentions2024-06: 45 mentions2024-07: 28 mentions2024-08: 17 mentions2024-09: 20 mentions2024-10: 28 mentions2024-11: 37 mentions2024-12: 17 mentions2025-01: 29 mentions2025-02: 59 mentions2025-03: 34 mentions2025-04: 26 mentions2025-05: 38 mentions2025-06: 20 mentions2025-07: 7 mentions2025-08: 35 mentions2025-09: 30 mentions2025-10: 32 mentions2025-11: 33 mentions2025-12: 16 mentions2026-01: 23 mentions2026-02: 58 mentions2026-03: 52 mentions2026-04: 60 mentions2026-05: 46 mentions2026-06: 4 mentions2024-012026-06

Machine-classified coverage tone

96.3% positive+0.5 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 17earnings report 16quarterly results 16annual earnings 15biomaterials 12stock indices 11tissue regeneration 10new executive 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-19–2026-06-11 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

DXCM

Dexcom

83,701 mentions
Products, pricing and logistics
72,915
Stock and valuation
596
Workplace and hiring
139
Other company context
5

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 83,701 records remained after filtering.

GMED

Globus Medical

61 mentions
Stock and valuation
27
Products, pricing and logistics
5
Workplace and hiring
4

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 61 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DXCM

Dexcom

through 2026-04-30
Earnings releases 61Lawsuits 41Leadership changes 18Company announcements 9Listing / IPO 4
  1. Earnings releases

    Dexcom (Nasdaq:DXCM) today posted first-quarter results that came in ahead of the Wall Street forecast. Shares of DXCM fell nearly 6% to $55.99 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) developer reported profits. of $199.5 million. That equals 51¢ per share on sales of $1.19 billion for the three months ended March 31, 2026.

  2. Leadership changes

    Upon his return, Sayer resumed his duties and responsibilities as executive chair.

  3. Lawsuits

    A California judge has dismissed several claims against Dexcom (Nasdaq:DXCM) officials related to alleged misrepresentation of sales efforts.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GMED

Globus Medical

through 2026-02-26
Earnings releases 42M&A 11Leadership changes 7Asset acquisitions 1
  1. Earnings releases

    Company Earnings Amt % of Sales Sales $826.4 Cost of Sales $261.1 31.6% R & D $36.1 4.4% Selling and Admin $318.5 38.5% Other $70.1 8.5% Net Earnings $140.6 17%

  2. Leadership changes

    Daniel Scavilla has resigned as President and Chief Executive Officer to pursue another opportunity as President and CEO of Dentsply Sirona.

  3. M&A

    Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MMSI

Merit

through 2026-04-02
Earnings releases 35M&A 13Asset acquisitions 6Leadership changes 4Company announcements 1
  1. M&A

    Merit Medical Systems has purchased US-based View Point Medical through a merger transaction, making the latter a wholly owned subsidiary.

  2. Earnings releases

    Merit delivered better-than-expected revenue and financial results in the fourth quarter

  3. Asset acquisitions

    Merit Medical Systems, Inc. (NASDAQ: MMSI) has agreed to acquire the C2 CryoBalloon technology and related assets from Pentax Medical, a division of HOYA Corporation, for up to USD 22 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

WST

West Pharmaceutical Services

through 2026-04-23
Earnings releases 42Leadership changes 8Lawsuits 3Company announcements 2Asset acquisitions 1
  1. Earnings releases

    West Pharmaceutical Services updated its Q2 2026 guidance to 2.050-2.120 EPS.

  2. Company announcements

    West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West’s contract services.

  3. Leadership changes

    West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IART

Integra LifeSciences

through 2026-02-26
Earnings releases 32Lawsuits 17Leadership changes 15M&A 8Company announcements 3
  1. Earnings releases

    Full-Year 2025 Reported revenues were $1,635.2 million, representing an increase of 1.5% on a reported basis and a decrease of 0.7% on an organic basis compared to full-year 2024.

  2. Leadership changes

    The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer.

  3. Regulatory

    Integra LifeSciences Corp., of Plainsboro, N.J.,received FDA approval to export its Integra Artifical Skinto Denmark. The product, which is under review by the FDA for marketing in the U.S., is used to restorefunctional dermal tissue in critically burned patients.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence
2019 extracted base$10.20B–$11.75B
2025 extracted forecast$11.50B–$21.52B
Implied source CAGR7.4%
increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records
Latest 12m volume+8.7%36648 vs 33721 records
Positive classified tone66.7%+5.2 pp vs prior four quarters
2024-01: 2,862 mentions2024-02: 2,508 mentions2024-03: 2,665 mentions2024-04: 2,848 mentions2024-05: 2,984 mentions2024-06: 2,155 mentions2024-07: 2,123 mentions2024-08: 2,108 mentions2024-09: 2,116 mentions2024-10: 2,483 mentions2024-11: 2,604 mentions2024-12: 2,045 mentions2025-01: 2,853 mentions2025-02: 5,160 mentions2025-03: 3,909 mentions2025-04: 3,553 mentions2025-05: 2,612 mentions2025-06: 1,780 mentions2025-07: 3,188 mentions2025-08: 7,906 mentions2025-09: 2,642 mentions2025-10: 2,462 mentions2025-11: 2,103 mentions2025-12: 2,450 mentions2026-01: 1,736 mentions2026-02: 4,268 mentions2026-03: 3,588 mentions2026-04: 4,213 mentions2026-05: 312 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates
7,802
medical drama series
7,076
cannabis legalization trends & economic impact
6,207
recreational marijuana usage
5,579
in-flight medical emergency protocols
4,688
medical marijuana laws & regulatory frameworks
3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 6–13. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Merit has the widest attention-readiness rank gap

It ranks #1 by measured news attention (72.4%) and #3 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Merit in Companies Radar

Dexcom shows a price-operating divergence to inspect

Its displayed filing-revenue change is +90.4% while its available monthly-close return is -32.5%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Dexcom in Companies Radar
Explanations

Attention measures coverage volume, not quality

Merit's 72.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Merit in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Dexcom's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 55/100 score.

Open Dexcom in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon